- Home
- FENC
as of 03-20-2026 3:34pm EST
$7.44
$0.21
-2.75%
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Fennec Pharmaceuticals Inc. (FENC) prepares to release earnings report on 24 Mar 2026.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 266.4M | IPO Year: | 2010 |
| Target Price: | $15.00 | AVG Volume (30 days): | 120.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | 96.67 |
| 52 Week Low/High: | $4.68 - $9.92 | Next Earning Date: | 03-24-2026 |
| Revenue: | $47,538,000 | Revenue Growth: | 123.69% |
| Revenue Growth (this year): | -3.33% | Revenue Growth (next year): | 70.78% |
| P/E Ratio: | -42.50 | Index: | N/A |
| Free Cash Flow: | 25.5M | FCF Growth: | N/A |
AI-Powered FENC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 74.05%
74.05%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
Raykov Rosty
Sell
Director
FENC Mar 2, 2026
Avg Cost/Share
$8.36
Shares
10,079
Total Value
$84,260.44
Owned After
103,996
SEC Form 4
Raykov Rosty
Sell
Director
FENC Feb 2, 2026
Avg Cost/Share
$7.76
Shares
10,349
Total Value
$80,308.24
Owned After
103,996
SEC Form 4
Raykov Rosty
Sell
Director
FENC Jan 2, 2026
Avg Cost/Share
$7.60
Shares
10,312
Total Value
$78,371.20
Owned After
103,996
SEC Form 4
Southpoint Capital Advisors LP
Sell
10% Owner
FENC Dec 24, 2025
Avg Cost/Share
$7.50
Shares
1,000,000
Total Value
$7,500,000.00
Owned After
2,744,741
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Raykov Rosty | FENC | Director | Mar 2, 2026 | Sell | $8.36 | 10,079 | $84,260.44 | 103,996 | |
| Raykov Rosty | FENC | Director | Feb 2, 2026 | Sell | $7.76 | 10,349 | $80,308.24 | 103,996 | |
| Raykov Rosty | FENC | Director | Jan 2, 2026 | Sell | $7.60 | 10,312 | $78,371.20 | 103,996 | |
| Southpoint Capital Advisors LP | FENC | 10% Owner | Dec 24, 2025 | Sell | $7.50 | 1,000,000 | $7,500,000.00 | 2,744,741 |
Earnings Transcripts
SEC 8-K filings with transcript text
2024 Q4 Q4 2024 Earnings
8-K BUY Mar 10, 2025 · 100% conf.
2024
Q4
Q4 2024 Earnings
8-K BUYMar 10, 2025 · 100% conf.
AI Prediction BUY
1D
-1.99%
$6.02
Act: +4.40%
5D
+2.59%
$6.30
Act: +2.93%
20D
+9.31%
$6.71
Act: -14.66%
Price: $6.14 Prob +5D: 100% AUC: 1.000
0001558370-25-002599
0001211583false00012115832025-03-102025-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 10, 2025
FENNEC PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
001-32295 (Commission File Number)
British Columbia, Canada
20-0442384
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC
27709
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (919) 636-4530
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12 of the Act:
Title of each class Trading symbol(s) Name of each exchange on which registered
Common shares, no par value
FENC
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 10, 2025, Fennec Pharmaceuticals Inc. issued a news release announcing full year and fourth quarter financial results for the period ended December 31, 2024. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
Exhibit 99.1 Press Release dated March 10, 2025
Exhibit 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
FENNEC PHARMACEUTICALS INC.
Date March 10, 2025 By: /s/ Robert Andrade
Robert Andrade Chief Financial Officer
2023 Q4 Q4 2023 Earnings
8-K Mar 25, 2024
2023
Q4
Q4 2023 Earnings
8-KMar 25, 2024
0001104659-24-038444
false 0001211583
0001211583
2024-03-21 2024-03-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 21, 2024
FENNEC
PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
001-32295
(Commission File Number)
British Columbia, Canada
20-0442384
(State or other jurisdiction of
incorporation)
(I.R.S. Employer Identification No.)
PO Box 13628, 68 TW Alexander Drive,
Research Triangle Park, NC
27709
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (919) 636-4530
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Title of each class Trading symbol(s) Name of each exchange on which
registered
Common
FENC, FRX
Nasdaq, TSX
Item 2.02. Results of Operations and Financial Condition.
On March 21, 2024, Fennec Pharmaceuticals Inc. issued a news release announcing full year and fourth quarter financial results for the period ended December 31, 2023. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
Exhibit 99.1 Press Release dated March 21, 2024
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
FENNEC PHARMACEUTICALS INC.
Date March 25, 2024 By: /s/ Robert Andrade
Robert Andrade
Chief Financial Officer
2023 Q4 Q4 2023 Earnings
8-K/A Mar 6, 2024
2023
Q4
Q4 2023 Earnings
8-K/AMar 6, 2024
0001104659-24-031470
false 0001211583
0001211583
2024-02-29 2024-02-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K/A
(Amendment No. 1)
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 29, 2024
FENNEC PHARMACEUTICALS
INC.
(Exact name of registrant as specified in its charter)
001-32295
(Commission File Number)
British Columbia, Canada
20-0442384
(State or other jurisdiction of
incorporation)
(I.R.S. Employer Identification
No.)
PO Box 13628, 68 TW Alexander Drive,
Research Triangle Park, NC
27709
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (919) 636-4530
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol(s) Name of each exchange on which
registered
Common shares, no par value
FENC
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Background.
This Amendment No. 1 to the Current Report on Form 8-K/A hereby amends and restates the Current Report on Form 8-K as filed with the Securities and Exchange Commission on February 29, 2024 to properly disclose the results of operations and financial condition of Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) under Item 2.02.
Item 2.02 Results of Operations and Financial Condition.
On February 29, 2024, Fennec issued a press release announcing financial results for the fourth quarter and full-year ended December 31, 2023. A copy of the Press Release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference in this Item 2.02. The press release did not include certain financial statements, related footnotes and certain other financial information that will be filed with the Securities and Exchange Commission as part of the Company’s Annual Report on Form 10-K.
The information and exhibit contained in this Item 2.02 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description
99.1Press Release dated February 29, 2024
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 6, 2024
FENNEC PHARMACEUTICALS INC.
By: /s/ Rostislav Raykov
Rostislav Raykov
Chief Executive Officer
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
MT Newswires
Sector Update: Health Care Stocks Increase in Afternoon Trading
📊
AI Sentiment
Positive
7/10
MT Newswires
Sector Update: Health Care
Compare FENC vs Leading Stocks
See how FENC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.